MARKET

NBIX

NBIX

Neurocrine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

93.23
+0.26
+0.28%
After Hours: 93.23 0 0.00% 16:22 03/05 EST
OPEN
93.85
PREV CLOSE
92.97
HIGH
93.98
LOW
88.15
VOLUME
2.12M
TURNOVER
--
52 WEEK HIGH
136.27
52 WEEK LOW
72.14
MARKET CAP
8.76B
P/E (TTM)
22.42
1D
5D
1M
3M
1Y
5Y
Analyst Actions: Credit Suisse Lowers Neurocrine Biosciences' Price Target to $101 From $105, Keeps Neutral Rating
MT Newswires · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Neurocrine (NBIX), Dynavax (DVAX)
SmarterAnalyst · 2d ago
Zoladex Market Report 2021 Growth Factors, Research Methodology With Impact of COIVD-19 and Global Forecast 2025
The Express Wire · 2d ago
Analyst Actions: RBC Capital Adjusts Neurocrine Biosciences' Price Target to $122 From $124, Maintains Outperform Rating
MT Newswires · 2d ago
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Bio-Techne (TECH) and Patterson Companies (PDCO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurocrine (NBIX), Bio-Techne (TECH) and Patterson Companies (PDCO).
SmarterAnalyst · 2d ago
Global Endometriosis Market 2021 Latest Trends, Product, Growing Demand, Growth, Key Companies, Regional Analysis & Forecast 2025
Mar 03, 2021 (The Expresswire) -- Adroit Market Research launched a study titled, “Global Endometriosis Market Size by Drug Type (NSAID’s, Gonadotropins...
The Express Wire · 4d ago
Neurocrine (NBIX) Receives a Buy from Oppenheimer
In a report released yesterday, Jay Olson from Oppenheimer assigned a Buy rating to Neurocrine (NBIX), with a price target of $145.00. The company's
SmarterAnalyst · 4d ago
Neurocrine (NBIX) Gets a Buy Rating from Raymond James
SmarterAnalyst · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBIX. Analyze the recent business situations of Neurocrine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBIX stock price target is 128.48 with a high estimate of 163.00 and a low estimate of 101.00.
EPS
Institutional Holdings
Institutions: 651
Institutional Holdings: 100.38M
% Owned: 106.85%
Shares Outstanding: 93.94M
TypeInstitutionsShares
Increased
139
8.84M
New
129
-781.22K
Decreased
148
8.24M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Independent Director
William Rastetter
Chief Executive Officer/Director
Kevin Gorman
Chief Financial Officer
Matt Abernethy
Chief Financial Officer
Matthew Abernethy
Chief Human Resource Officer
Julie Cooke
Other
Eric Benevich
Other
David Boyer
Other
Haig Bozigian
Other
Kyle Gano
Other
Dimitri Grigoriadis
Other
Malcolm Lloyd-Smith
Other
Eiry Roberts
Independent Director
.. ..
Secretary
Darin Lippoldt
Independent Director
Gary Lyons
Independent Director
George Morrow
Independent Director
Leslie Norwalk
Independent Director
Richard Pops
Independent Director
Shalini Sharp
Independent Director
Stephen Sherwin
No Data
  • All
  • Financials
  • Insiders
More
About NBIX
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Webull offers kinds of Neurocrine Biosciences, Inc. stock information, including NASDAQ:NBIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBIX stock methods without spending real money on the virtual paper trading platform.